Low-dose aspirin increases aspirin resistance in patients with coronary artery disease
|
|
- Sara Kelly
- 6 years ago
- Views:
Transcription
1 The American Journal of Medicine (2005) 118, CLINICAL RESEARCH STUDY AJM Theme Issue: CARDIOLOGY Low-dose aspirin increases aspirin resistance in patients with coronary artery disease Pui-Yin Lee, MBBS, Wai-Hong Chen, MBBS, FACC, William Ng, MBBS, FACC, Xi Cheng, MD, Jeanette Yat-Yin Kwok, RN, Hung-Fat Tse, MD, FACC, Chu-Pak Lau, MD, FACC Department of Medicine, The University of Hong Kong, Queen Mary Hospital. KEYWORDS: Aspirin; Coronary disease; Platelets ABSTRACT PURPOSE: We sought to investigate the association of aspirin dose and aspirin resistance in stable coronary artery disease patients measured by a point-of-care assay. METHODS: We studied 468 consecutive stable coronary artery disease patients in a referral cardiac center who were taking aspirin 80 to 325 mg daily for 4 weeks. The VerifyNow Aspirin (Ultegra RPFA-ASA, Accumetrics Inc, San Diego, Calif) was used to determine aspirin responsiveness. An aspirin reaction unit (ARU) 550 indicates the absence of aspirin-induced platelet dysfunction, based on correlation with epinephrine-induced light transmission aggregometry. Demographic and clinical data were collected to analyze the predictors of aspirin resistance. RESULTS: Aspirin resistance was noted in 128 (27.4%) patients. Univariate predictors of aspirin resistance include elderly (P 0.002), women (P 0.001), anemia (P 0.001), renal insufficiency (P 0.009) and aspirin dose 100mg (P 0.004). Multivariate analysis revealed hemoglobin (odds ratio [OR] 0.6; 95% confidence interval [CI] 0.51 to 0.69; P 0.001) and aspirin dose 100 mg (OR 2.23; 95% CI 1.12 to 4.44; P 0.022) to be independent predictors of aspirin resistance. Daily aspirin dose 100 mg was associated with increased prevalence of aspirin resistance compared with 150 mg and 300 mg daily (30.2% vs 16.7% vs 0%, P ). CONCLUSION: A 100 mg or less daily dose of aspirin, which may have lower side effects, is associated with a higher incidence of aspirin resistance in patients with coronary artery disease. Prospective randomized studies are warranted to elucidate the optimal aspirin dosage for preventing ischemic complications of atherothrombotic disease Elsevier Inc. All rights reserved. Requests for reprints should be addressed to Wai-Hong Chen, MBBS, FACC, Division of Cardiology, Department of Medicine, The University of Hong Kong, Queen Mary Hospital, Hong Kong, China. address: whchen@hku.hk. The pivotal role of platelet in the initiation of atherothrombosis supports the clinical usefulness of aspirin in reducing ischemic cardiovascular events in patients with atherosclerosis. 1 However, aspirin has been shown to have variable antiplatelet activity in individual patients. 2 4 Recent studies showed that patients with inadequate platelet inhibition by aspirin are associated with a higher incidence of reocclusion after peripheral angioplasty, 5 more myonecrosis after elective percutaneous coronary intervention, 3 and more myocardial infarction, stroke, and cardiovascular death among stable cardiovascular patients. 4,6 Although low-dose aspirin ( mg daily) was suggested to be the rational strategy in order to maximize its efficacy and to minimize its toxicity, 1,7 the effect of aspirin dose on the prevalence of aspirin resistance has not been studied. This /$ -see front matter 2005 Elsevier Inc. All rights reserved. doi: /j.amjmed
2 724 The American Journal of Medicine, Vol 118, No 7, July 2005 study examines the prevalence, predictors, and the effect of aspirin dose on aspirin resistance in patients with documented coronary artery disease using the point-of-care VerifyNow Aspirin (Ultegra RPFA-ASA, Accumetrics, San Diego, Calif). Methods Study group A total of 468 patients with stable coronary artery disease and aspirin use of 80 to 325 mg daily for 4 weeks were prospectively enrolled between October 2002 and May Because all patients had regular follow-up in our institution, the aspirin dose could be retrieved from computer prescription record. Aspirin dose and compliance were verified with patients before recruitment. Coronary artery disease was documented by cardiac catheterization, previous history of myocardial infarction, or previous percutaneous coronary intervention or coronary artery bypass surgery. Exclusion criteria included: ingestion of nonsteroidal anti-inflammatory drugs, dipyridamole, clopidogrel, or ticlopidine within 7 days before enrollment; administration of heparin or low-molecularweight heparin within 24 hours before enrollment; family or personal history of bleeding disorders; platelet count / L or / L; hemoglobin 8 g/dl; and major surgery a week before enrollment. Patient records were reviewed and patients were interviewed to determine the dose of aspirin taken over the past 4 weeks. Renal insufficiency was defined as serum creatinine 140 mol/l. Blood samples All patients recruited would have blood sample collection on the same day. Aspirin-induced platelet inhibition was measured using a commercially available point-of-care assay, the VerifyNow Aspirin. Two milliliters citratedanticoagulated blood was added to cartridges, which contain fibrinogen-coated beads and platelet agonists. If aspirin has produced the expected antiplatelet effect, fibrinogen-coated beads will not agglutinate, and light transmission will not increase. The result is expressed as aspirin reaction unit (ARU). An ARU 550 indicates the absence of aspirin-induced platelet dysfunction, based on correlation with epinephrine-induced light transmission aggregometry in aspirin-naïve patient tested prior to and 2 to 30 h after aspirin (325 mg) ingestion, and is defined as aspirin-resistant (Ultegra RPFA-ASA package insert). Compared with light aggregometry, the sensitivity and the specificity of this assay were 92% and 85%, respectively. The coefficient of variance was 2.5% on repeated measures within patients. The between-patient coefficient of variance was 12.5% for baseline samples and 15% for post-aspirin samples. Statistical analysis Categorical variables are presented as frequencies and percentages. Continuous variables are presented as means SD. Categorical variables were compared using chi-squared tests or Fisher s exact tests if appropriate. Student s t test or Mann-Whitney U test (if not normally distributed) were used to compare the continuous variables between 2 groups. A logistic regression analysis using forward technique was employed to determine significant predictors of aspirin resistance. A P value 0.05 was considered statistically significant. All analyses were performed using SPSS 12.0 (SPSS Inc., Chicago, Ill). Results The baseline clinical characteristics of the patients are listed in Table 1. Of a total of 468 patients enrolled, 128 (27.4%) were found to be aspirin resistant. Patients who were aspirin resistant were older ( years vs years, P 0.002), more likely to be women (46.1% vs 25.3%, P 0.001), and had a slightly lower hemoglobin level ( years vs g/dl, P 0.001) compared with patients who were aspirin sensitive. Renal insufficiency was associated with aspirin resistance (18.8% vs 9.7%, P 0.009). The mean dosage of aspirin taken was lower in aspirin-resistant patients ( mg vs mg, P 0.001). The 2 groups had similar prevalence of cardiovascular risk factors and severity of coronary artery disease. To further evaluate the effect of different aspirin dosages, we performed analysis to determine the percentage of aspirin-sensitive patients in accordance with the aspirin dosage (Figure). In this cohort, 384 (82.1%) patients were taking mg aspirin daily, whereas 72 (15.4%) and 12 (2.5%) patients were taking 150 mg and 300 mg aspirin daily, respectively. It was noted that 69.8% of patients taking 100 mg were aspirin sensitive, compared with 83.3% and 100% of patients who were taking 150 mg and 300 mg, respectively (P ). Univariate and multivariate analysis of predictors for aspirin resistance are shown in Table 2. Variables associated with aspirin resistance by univariate analysis were age (P 0.002), women (P 0.001), hemoglobin level (P 0.001), renal insufficiency (P 0.009) and aspirin dose (P 0.004). Multivariate analysis revealed hemoglobin level (odds ratio [OR] 0.6; 95% confidence interval [CI] 0.51 to 0.69; P 0.001) and aspirin dose 100 mg (OR 2.23; 95% CI 1.12 to 4.44; P 0.022) to be independent predictors of aspirin resistance in this cohort of patients with documented coronary artery disease.
3 Lee et al Aspirin dose, aspirin resistance and coronary artery disease 725 Table 1 Baseline clinical characteristics according to aspirin sensitivity status ASA-S (n 340) ASA-R (n 128) P value Age, years Women, n (%) 86 (25.3%) 59 (46.1%) Weight, kg Body mass index, kg/m Diabetes, n (%) 117 (34.4%) 50 (39.1%) Hypertension, n (%) 223 (65.6%) 93 (72.7%) Hyperlipidemia, n (%) 233 (68.5%) 88 (68.8%) Current smoker, n (%) 48 (14.1%) 14 (10.9%) Prior myocardial infarction, n (%) 104 (30.6%) 43 (33.6%) Hemoglobin, g/dl White cell count, 109/L Platelet count, 109/L or 3-vessel coronary artery disease, n (%) 161 (47.4%) 65 (50.8%) Serum creatinine, mol/l Renal insufficiency, n (%) 33 (9.7%) 24 (18.8%) Aspirin reaction unit (ARU) Aspirin dosage (mg) ASA-S aspirin-sensitive; ASA-R aspirin-resistant. Body mass index is calculated as the weight in kilograms divided by the square of height in meters. Discussion Our results showed that up to 27.4% of patients with stable coronary artery disease were aspirin resistant as measured by the VerifyNow Aspirin. This is the largest study so far studying the prevalence of aspirin resistance in patients with coronary artery disease. We also showed that low hemoglobin level and aspirin dose predicted aspirin resistance in this cohort. Gum et al, using optical platelet aggregation, showed that 29.3% of the patients taking 325 mg aspirin daily were either aspirin resistant or semiresponder. 8 Similar to our findings, they found aspirin-resistant patients or aspirin Figure Effect of aspirin dose on percentage of aspirin-sensitive patients (ARU 550). ASA aspirin; ASA-S aspirin sensitive; ASA-R aspirin resistant. semiresponders were more likely to be women, be an older age, and have a lower hemoglobin. However, no significant demographic differences between aspirin-resistant and sensitive patients were identified using the platelet function analyzer-100 to define aspirin responsiveness. Wang et al, using also the VerifyNow Aspirin, found that low platelet count and low hematocrit were significant predictors of aspirin resistance. 9 Aspirin dose was not predictive of aspirin resistance. However, the patients recruited (n 422) were more heterogeneous in that 64% of patients had coronary artery disease, 7% had cerebral vascular accidents, and 8% had peripheral vascular disease. In addition, in contrast to our study, most (66%) of their patients were taking higher doses of aspirin ( 162 mg) and only 33% were taking 81 mg daily aspirin. Together with our data, all these observational studies showed that around 1 in 4 patients were aspirin resistant as determined by different platelet assays. The underlying mechanism for association between low hemoglobin and aspirin resistance was not clear, but this may explain the observation that anemia was related to poor clinical outcomes in patients with established coronary artery disease. 10,11 The use of low-dose versus intermediate- or high-dose aspirin is still controversial. In the recent Antithrombotic Trialists Collaboration, 1 which was a meta-analysis of 287 studies, high-dose aspirin had a similar proportional risk reduction as low-dose aspirin. Because high-dose aspirin was associated with more gastrointestinal side effects and bleeding, low-dose aspirin was generally preferred and recommended. However, laboratory tests showed that highdose aspirin was associated with more complete platelet inbibition. 12,13 Recently, in a pooled analysis of more than
4 726 The American Journal of Medicine, Vol 118, No 7, July 2005 Table 2 Univariate and multivariate analysis of predictors of aspirin resistance Variables -coefficient Standard Error P value OR 95% CI Univariate predictors Age , 1.05 Female , 3.86 Hemoglobin , 0.68 Renal insufficiency , 3.80 ASA dose 100 mg , 4.96 Multivariate predictors Hemoglobin , 0.69 ASA dose 100 mg , patients with unstable angina and acute myocardial infarction, Quinn et al 14 observed that intermediate-dose aspirin, compared with low-dose aspirin, was associated with less frequent myocardial infarction. There was no difference in the incidence of death and there were more strokes among patients with high-dose aspirin. In a randomized study involving an oral glycoprotein IIb/IIIa antagonist lotrafiban, Topol et al found that high-dose ( 162 mg/day) aspirin was associated with decreased mortality. 15 On the contrary, in the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) study, Peters et al showed that high-dose aspirin, with or without clopidogrel, was not associated with fewer clinical events 16 but more major bleedings. Our study showed that low-dose aspirin was associated with more aspirin resistance. Whether or not escalating the aspirin dose among aspirin-resistant patients would reverse their aspirin responsiveness and hence their clinical risks remains to be proved. A large-scale prospective study on aspirin dose and aspirin resistance, preferably together with clinical outcomes, will be needed. Meanwhile, further studies in female, elderly, and chronic renal failure patients are needed to elucidate the role of aspirin responsiveness in these high-risk groups of patients. Our data also showed that, with the use of the VerifyNow Aspirin, aspirin-resistant patients would be readily identified. Compared with conventional laboratory methods for evaluation of platelet function, which are complicated and time consuming, the VerifyNow Aspirin is easy to use and readily accessible to physicians in clinical practice. This assay was recently reported to have a high correlation with conventional aggregometry in assessing platelet function among patients with stable cardiovascular disease. 17 Last, further studies on the long-term outcomes of aspirin-resistant patients would be needed. Although we believe that antiplatelet therapy should be individualized, the use of higher dose aspirin or alternative antiplatelet (eg, clopidogrel) in these patients will not be advocated until more data are available. There are some limitations to this study. First, this is a nonrandomized observational study. Unrecognized confounders may influence the prevalence of parameters among aspirin-sensitive and resistant patients. Second, we relied on computer prescription records to determine the aspirin dose patients were taking. However, we did try to confirm the dose of aspirin taken by verifying with the patients. Meanwhile, patients compliance to take aspirin was not ascertained. Conclusion Aspirin resistance is noted in a significant number of stable coronary artery disease patients, and low aspirin dose is associated with a higher incidence of aspirin resistance. Prospective randomized studies to evaluate the safety and efficacy of higher dose aspirin or alternative antiplatelet agents in aspirin-resistant patients are warranted. References 1. Antithrombotic Trialists Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ. 2002; 324: Andersen K, Hurlen M, Arnesen H, Seljeflot I. Aspirin non-responsiveness as measured by PFA-100 in patients with coronary artery disease. Thromb Res. 2002;108: Chen WH, Lee PY, Ng W, Tse HF, Lau CP. Aspirin resistance is associated with a high incidence of myonecrosis after non-urgent percutaneous coronary intervention despite clopidogrel pretreatment. J Am Coll Cardiol. 2004;43: Eikelboom JW, Hirsh J, Weitz JI, Johnston M, Yi Q, Yusuf S. Aspirinresistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events. Circulation. 2002;105: Mueller MR, Salat A, Stangl P, et al. Variable platelet response to low-dose ASA and the risk of limb deterioration in patients submitted to peripheral arterial angioplasty. Thromb Haemost. 1997;78: Gum PA, Kottke-Marchant K, Welsh PA, White J, Topol EJ. A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease. JAm Coll Cardiol. 2003;41: Patrono C, Coller B, FitzGerald GA, Hirsh J, Roth G. Platelet-active drugs: the relationships among dose, effectiveness, and side effects: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004;126:234S 264S. 8. Gum PA, Kottke-Marchant K, Poggio ED, et al. Profile and prevalence of aspirin resistance in patients with cardiovascular disease. Am J Cardiol. 2001;88:
5 Lee et al Aspirin dose, aspirin resistance and coronary artery disease Wang JC, Aucoin-Barry D, Manuelian D, et al. Incidence of aspirin nonresponsiveness using the Ultegra Rapid Platelet Function Assay- ASA. Am J Cardiol. 2003;92: Rao SV, Jollis JG, Harrington RA, et al. Relationship of blood transfusion and clinical outcomes in patients with acute coronary syndromes. JAMA. 2004;292: Zimmermann N, Wenk A, Kim U, et al. Functional and biochemical evaluation of platelet aspirin resistance after coronary artery bypass surgery. Circulation. 2003;108: Hart RG, Leonard AD, Talbert RL, et al. Aspirin dosage and thromboxane synthesis in patients with vascular disease. Pharmacotherapy. 2003;23: Helgason CM, Bolin KM, Hoff JA, et al. Development of aspirin resistance in persons with previous ischemic stroke. Stroke. 1994;25: Quinn MJ, Aronow HD, Califf RM, et al. Aspirin dose and six-month outcome after an acute coronary syndrome. J Am Coll Cardiol. 2004; 43: Topol EJ, Easton D, Harrington RA, et al. Randomized, double-blind, placebo-controlled, international trial of the oral IIb/IIIa antagonist lotrafiban in coronary and cerebrovascular disease. Circulation. 2003; 108: Peters RJ, Mehta SR, Fox KA, et al. Effects of aspirin dose when used alone or in combination with clopidogrel in patients with acute coronary syndromes: observations from the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) study. Circulation. 2003;108: Malinin A, Spergling M, Muhlestein B, Steinhubl S, Serebruany V. Assessing aspirin responsiveness in subjects with multiple risk factors for vascular disease with a rapid platelet function analyzer. Blood Coagul Fibrinolysis. 2004;15:
Clopidogrel has been evaluated in clinical trials that included cardiovascular patients
REVIEW ARTICLE Comparative Benefits of Clopidogrel and Aspirin in High-Risk Patient Populations Lessons From the CAPRIE and CURE Studies Jack Hirsh, CM, MD, FRCPC, FRACP, FRSC, DSc; Deepak L. Bhatt, MD,
More informationAspirin Resistance in Patients with Chronic Renal Failure (P 5325)
Aspirin Resistance in Patients with Chronic Renal Failure (P 5325) Beste Ozben Sadic 1, Azra Tanrikulu 1, Mehmet Koc 2, Tomris Ozben 3, Oguz Caymaz 1 1 Marmara University, Faculty of Medicine, Department
More informationAspirin resistance among patients with recurrent non-cardioembolic stroke detected by rapid platelet function analyzer
Neurology Asia 2007; 12 : 89 95 ORIGINAL ARTICLES Aspirin resistance among patients with recurrent non-cardioembolic stroke detected by rapid platelet function analyzer Jose C NAVARRO MD MSc, Annabelle
More informationCase presentation 1: Mr F. is a
CLINICIAN UPDATE Platelet Function Testing in Cardiovascular Diseases Alan D. Michelson, MD Case presentation 1: Mr F. is a 60-year-old man with unstable angina who takes aspirin, 81 mg/day. A platelet
More informationAspirin to Prevent Heart Attack and Stroke: What s the Right Dose?
The American Journal of Medicine (2006) 119, 198-202 REVIEW Aspirin to Prevent Heart Attack and Stroke: What s the Right Dose? James E. Dalen, MD, MPH Professor Emeritus, University of Arizona, Tucson
More informationAnti-platelet therapies and dual inhibition in practice
Anti-platelet therapies and dual inhibition in practice Therapeutics; Sept. 25 th 2007 Craig Williams, Pharm.D. Associate Professor of Pharmacy Objectives 1. Understand the pharmacology of thienopyridine
More informationPlatelet function testing in cardiovascular diseases
Hematology, 2005; 10 Supplement 1: 132 /137 PLATELET DISORDERS Platelet function testing in cardiovascular diseases ALAN D. MICHELSON From the Center for Platelet Function Studies, Departments of Pediatrics,
More informationREVIEW ARTICLE. Association of Laboratory-Defined Aspirin Resistance With a Higher Risk of Recurrent Cardiovascular Events
REVIEW ARTICLE Association of Laboratory-Defined Aspirin Resistance With a Higher Risk of Recurrent Cardiovascular Events A Systematic Review and Meta-analysis Jaapjan D. Snoep, MSc; Marcel M. C. Hovens,
More informationRole of Clopidogrel in Acute Coronary Syndromes. Hossam Kandil,, MD. Professor of Cardiology Cairo University
Role of Clopidogrel in Acute Coronary Syndromes Hossam Kandil,, MD Professor of Cardiology Cairo University ACS Treatment Strategies Reperfusion/Revascularization Therapy Thrombolysis PCI (with/ without
More informationAntiplatelet agents treatment
Session III Comprehensive management of diabetic patients Antiplatelet agents treatment Chonnam National University Hospital Department of Internal Medicine Dong-Hyeok Cho CONTENTS Introduction Prothrombotic
More information1. Introduction: Page 5. International Multispecialty Journal of Health (IMJH) [Vol-1, Issue-4, June- 2015]
Aspirin Resistance: A Review Dr. Kamlesh Sharma 1, Dr. Lokendra Sharma 2, Dr. Monica Jain 3, Dr. Gopal Jhalani 4, Dr. Shivankan Kakar 5, Dr. Harsh Yadav 6 1,3 Professor, Department of Medicine, SMS Medical
More informationAbstract Background: Methods: Results: Conclusions:
Two-Year Clinical and Angiographic Outcomes of Overlapping Sirolimusversus Paclitaxel- Eluting Stents in the Treatment of Diffuse Long Coronary Lesions Kang-Yin Chen 1,2, Seung-Woon Rha 1, Yong-Jian Li
More informationDECLARATION OF CONFLICT OF INTEREST. Lecture fees: AstraZeneca, Ely Lilly, Merck.
DECLARATION OF CONFLICT OF INTEREST Lecture fees: AstraZeneca, Ely Lilly, Merck. Risk of stopping dual therapy. S D Kristensen, FESC Aarhus Denmark Acute coronary syndrome: coronary thrombus Platelets
More informationACCP Cardiology PRN Journal Club
ACCP Cardiology PRN Journal Club 1 Optimising Crossover from Ticagrelor to Clopidogrel in Patients with Acute Coronary Syndrome [CAPITAL OPTI-CROSS] Monique Conway, PharmD, BCPS PGY-2 Cardiology Pharmacy
More informationThe Impact of Aspirin Resistance on the Long-term Cardiovascular Mortality in Patients with Non-ST Segment Elevation Acute Coronary Syndromes
The Impact of Aspirin Resistance on the Long-term Cardiovascular Mortality in Patients with Non-ST Segment Elevation Acute Coronary Syndromes Address for correspondence: Michael N. Zairis, MD, PhD 40 Acti
More informationTo provide information on the use of acetyl salicylic acid in the treatment and prevention of vascular events.
ACETYL SALICYLIC ACID TARGET AUDIENCE: All Canadian health care professionals. OBJECTIVE: To provide information on the use of acetyl salicylic acid in the treatment and prevention of vascular events.
More informationSimple, Rapid Antiplatelet Therapy Response Assessment
Simple, Rapid Antiplatelet Therapy Response Assessment Acute Care Diagnostics Antiplatelet therapy. Is it working? At least 1 in 3 patients on antiplatelet therapies do not receive the intended physiological
More informationNg, W; Wong, WM; Chen, WH; Tse, HF; Lee, PY; Lai, KC; Li, SW; Ng, M; Lam, KF; Cheng, X; Lau, CP
Title Author(s) Incidence and predictors of upper gastrointestinal bleeding in patients receiving low-dose aspirin for secondary prevention of cardiovascular events in patients with coronary artery disease
More informationCangrelor: Is it the new CHAMPION for PCI? Robert Barcelona, PharmD, BCPS Clinical Pharmacy Specialist, Cardiac Intensive Care Unit November 13, 2015
Cangrelor: Is it the new CHAMPION for PCI? Robert Barcelona, PharmD, BCPS Clinical Pharmacy Specialist, Cardiac Intensive Care Unit November 13, 2015 Objectives Review the pharmacology and pharmacokinetic
More informationSupplementary Table S1: Proportion of missing values presents in the original dataset
Supplementary Table S1: Proportion of missing values presents in the original dataset Variable Included (%) Missing (%) Age 89067 (100.0) 0 (0.0) Gender 89067 (100.0) 0 (0.0) Smoking status 80706 (90.6)
More informationInter-regional differences and outcome in unstable angina
European Heart Journal (2000) 21, 1433 1439 doi:10.1053/euhj.1999.1983, available online at http://www.idealibrary.com on Inter-regional differences and outcome in unstable angina Analysis of the International
More informationDownloaded from:
Antithrombotic Trialists Collaboration. (inc. Meade, TW), (2002) Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high
More informationAspirin Resistance and Atherothrombotic Disease
Journal of the American College of Cardiology Vol. 46, No. 6, 2005 2005 by the American College of Cardiology Foundation ISSN 0735-1097/05/$30.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2004.08.070
More informationAntiplatelet therapy reduces the risk of major adverse cardiovascular events. Aspirin Resistance Predicts Adverse Cardiovascular Events
Clinical Investigation Tilak Pasala, MD, MRCP Jennifer Soo Hoo, MD Mary Kate Lockhart, MD Rehan Waheed, MD Prasanna Sengodan, MD Jeffrey Alexander, MD Sanjay Gandhi, MD, FSCAI Key words: Aspirin/therapeutic
More informationNew insights in stent thrombosis: Platelet function monitoring. Franz-Josef Neumann Herz-Zentrum Bad Krozingen
New insights in stent thrombosis: Platelet function monitoring Franz-Josef Neumann Herz-Zentrum Bad Krozingen New insights in stent thrombosis: Platelet function monitoring Variability of residual platelet
More informationThe Effects of Aspirin and Clopidogrel Response on Myonecrosis After Percutaneous Coronary Intervention
JACC: CARDIOVASCULAR INTERVENTIONS VOL. 1, NO. 6, 2008 2008 BY THE AMERICAN COLLEGE OF CARDIOLOGY FOUNDATION ISSN 1936-8798/08/$34.00 PUBLISHED BY ELSEVIER INC. DOI: 10.1016/j.jcin.2008.08.017 The Effects
More informationFACTOR Xa AND PAR-1 BLOCKER : ATLAS-2, APPRAISE-2 & TRACER TRIALS
New Horizons In Atherothrombosis Treatment 2012 순환기춘계학술대회 FACTOR Xa AND PAR-1 BLOCKER : ATLAS-2, APPRAISE-2 & TRACER TRIALS Division of Cardiology, Jeonbuk National University Medical School Jei Keon Chae,
More informationDental Management Considerations for Patients on Antithrombotic Therapy
Dental Management Considerations for Patients on Antithrombotic Therapy Warfarin and Antiplatelet Joel J. Napeñas DDS FDSRCS(Ed) Program Director General Practice Residency Program Department of Oral Medicine
More informationCardiovascular Health Nova Scotia Update to Antiplatelet Sections of the Nova Scotia Guidelines for Acute Coronary Syndromes, 2008.
Cardiovascular Health Nova Scotia Update to Antiplatelet Sections of the Nova Scotia Guidelines for Acute Coronary Syndromes, 2008. ST Elevation Myocardial Infarction (STEMI)-Acute Coronary Syndrome Guidelines:
More informationCOMPARISON OF LOADING DOSE OF 300mg VERSUS 600mg OF CLOPIDOGREL ON PLATELET AGGREGTION IN PATIENTS WITH CORONARY ARTERY DISEASE
VOL. 39 NO. 3 4 JULY - DECEMBER 2006 PAKISTAN HEART JOURNAL COMPARISON OF LOADING DOSE OF 300mg VERSUS 600mg OF CLOPIDOGREL ON PLATELET AGGREGTION IN PATIENTS WITH CORONARY ARTERY DISEASE SUMMARY MOHAMMAD
More informationClinical Study Age Differences in Long Term Outcomes of Coronary Patients Treated with Drug Eluting Stents at a Tertiary Medical Center
Aging Research Volume 2013, Article ID 471026, 4 pages http://dx.doi.org/10.1155/2013/471026 Clinical Study Age Differences in Long Term Outcomes of Coronary Patients Treated with Drug Eluting Stents at
More informationAsif Serajian DO FACC FSCAI
Anticoagulation and Antiplatelet update: A case based approach Asif Serajian DO FACC FSCAI No disclosures relevant to this talk Objectives 1. Discuss the indication for antiplatelet therapy for cardiac
More informationOral Antiplatelet Therapy in PCI/ACS. Dominick J. Angiolillo, MD, PhD, FACC, FESC Director of Cardiovascular Research Assistant Professor of Medicine
Oral Antiplatelet Therapy in PCI/ACS Dominick J. Angiolillo, MD, PhD, FACC, FESC Director of Cardiovascular Research Assistant Professor of Medicine Basic Concepts Thrombus Formation Two key elements:
More informationOptimal medical therapy in patients with stable CAD
Optimal medical therapy in patients with stable CAD Robert Storey Professor of Cardiology, University of Sheffield and Academic Director and Honorary Consultant Cardiologist, Cardiology and Cardiothoracic
More informationAspirin Resistance: Current Status
REVIEW ARTICLE JIACM 2007; 8(1): 72-7 Aspirin Resistance: Current Status Aniket Puri* Abstract Aspirin resistance is considered to be an enigma, and the data available on it is scarce. Various laboratory
More informationDose-Related Effect of Aspirin on Laboratory-Defined Platelet Aggregation and Clinical Outcome After Coronary Stenting
RESEARCH Dose-Related Effect of Aspirin on Laboratory-Defined Platelet Aggregation and Clinical Outcome After Coronary Stenting Javad Kojuri, 1 Yadollah Mahmoody, 1 Bardia Zangbar Sabegh, 1 Mansoor Jannati,
More informationClinical Investigation and Reports
Clinical Investigation and Reports Relationship of Activated Partial Thromboplastin Time to Coronary Events and Bleeding in Patients With Acute Coronary Syndromes Who Receive Heparin Sonia S. Anand, MD,
More informationBalancing Efficacy and Safety of P2Y12 Inhibitors for ACS Patients
SYP.CLO-A.16.07.01 Balancing Efficacy and Safety of P2Y12 Inhibitors for ACS Patients dr. Hariadi Hariawan, Sp.PD, Sp.JP (K) TOPICS Efficacy Safety Consideration from Currently Available Antiplatelet Agents
More informationJournal of the American College of Cardiology Vol. 50, No. 19, by the American College of Cardiology Foundation ISSN /07/$32.
Journal of the American College of Cardiology Vol. 50, No. 19, 2007 2007 by the American College of Cardiology Foundation ISSN 0735-1097/07/$32.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2007.07.058
More informationPrevalence and Risk Factors for Aspirin and Clopidogrel Resistance in Patients with Coronary Artery Disease or Ischemic Cerebrovascular Disease
Available online at www.annclinlabsci.org Annals of Clinical & Laboratory Science, vol. 39, no. 3, 2009 289 Prevalence and Risk Factors for Aspirin and Clopidogrel Resistance in Patients with Coronary
More information( Aspirin ) ( Stroke ) ( Dosage ) ( Diabetes ) ( Metabolic syndrome ) ( Primary prevention ) Aspirin Aspirin Aspirin. Aspirin.
2007 18 1-10 ( 75 150 mg/day ) ( American Heart Association AHA ) ( American Diabetes Association ADA ) 75 150 mg/day ( ) ( ) ( Stroke ) ( Dosage ) ( Diabetes ) ( Metabolic syndrome ) ( Primary prevention
More informationStephan Windecker Department of Cardiology Swiss Cardiovascular Center and Clinical Trials Unit Bern Bern University Hospital, Switzerland
Advances in Antiplatelet Therapy in PCI and ACS Stephan Windecker Department of Cardiology Swiss Cardiovascular Center and Clinical Trials Unit Bern Bern University Hospital, Switzerland Targets for Platelet
More informationMeasurement of Antiplatelet Therapeutic Efficacy
Measurement of Antiplatelet Therapeutic Efficacy Bonnie H. Weiner MD MSEC MBA FSCAI FACC FAHA Professor of Medicine Director, Interventional Cardiology Research St Vincent Hospital Worcester MA Disclosure
More informationISAR-CHOICE 2. Randomized Trial of 75 mg vs 150 mg of Daily Clopidogrel in Patients Undergoing PCI
ISAR-CHOICE 2 Randomized Trial of 75 mg vs 150 mg of Daily Clopidogrel in Patients Undergoing PCI Adnan Kastrati Deutsches Herzzentrum, Munich, GERMANY Variability in Platelet Response to Clopidogrel Serebruany
More informationThe ELAPSE (Evaluation of Long-Term Clopidogrel Antiplatelet and Systemic Anti-Inflammatory Effects) Study
Journal of the American College of Cardiology Vol. 52, No. 23, 2008 2008 by the American College of Cardiology Foundation ISSN 0735-1097/08/$34.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2008.08.047
More informationNOVEL ANTI-THROMBOTIC THERAPIES FOR ACUTE CORONARY SYNDROME: DIRECT THROMBIN INHIBITORS
Judd E. Hollander, MD Professor, Clinical Research Director, Department of Emergency Medicine University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania OBJECTIVES: 1. Discuss the concept
More informationP2Y 12 blockade. To load or not to load before the cath lab?
UPDATE ON ANTITHROMBOTICS IN ACUTE CORONARY SYNDROMES P2Y 12 blockade. To load or not to load before the cath lab? Franz-Josef Neumann Personal: None Institutional: Conflict of Interest Speaker honoraria,
More informationLearning Objectives. Epidemiology of Acute Coronary Syndrome
Cardiovascular Update: Antiplatelet therapy in acute coronary syndromes PHILLIP WEEKS, PHARM.D., BCPS-AQ CARDIOLOGY Learning Objectives Interpret guidelines as they relate to constructing an antiplatelet
More informationVerifyNow Reference Guide For use outside the U.S. only
VerifyNow Reference Guide For use outside the U.S. only VerifyNow P2Y12 Test Pre-surgical Application Studies show that there is patient variability in response to P2Y12 inhibitors 7. It has been recommended
More informationDisclosures. Theodore A. Bass MD, FSCAI. The following relationships exist related to this presentation. None
SCAI Fellows Course December 10, 2013 Disclosures Theodore A. Bass MD, FSCAI The following relationships exist related to this presentation None Current Controversies on DAPT in PCI Which drug? When to
More informationPOCT in the Management of Antiplatelet Therapy Patient Response, Treatment Optimization and Personalized Medicine
POCT in the Management of Antiplatelet Therapy Patient Response, Treatment Optimization and Personalized Medicine Jackie Coleman, Ph.D. Director of Scientific Affairs Accumetrics, Inc. San Diego, CA Goals
More informationArteriopatie periferiche. Trattamento delle arteriopatie periferiche: AVK versus Antiaggregante
Arteriopatie periferiche Trattamento delle arteriopatie periferiche: AVK versus Antiaggregante Anna Falanga USC Immunoematologia e Medicina Trasfusionale ASST Papa Giovanni XXIII, Bergamo Obiettivi della
More informationThe secondary prevention of ischemic stroke is aided by the use of antiplatelet therapy,
NEUROLOGICAL REVIEW SECTION EDITOR: DAVID E. LEASURE, MD Results of the Management of Atherothrombosis With Clopidogrel in High-Risk atients Trial Implications for the Neurologist Marc Fisher, MD The secondary
More informationAspirin at the Intersection of Antiplatelet and Anticoagulant Therapy An Act of Commission?
Aspirin at the Intersection of Antiplatelet and Anticoagulant Therapy An Act of Commission? Ty J. Gluckman, MD, FACC, FAHA Medical Director, Center for Cardiovascular Analytics, Research and Data Science
More informationClopidogrel Date: 15 July 2008
These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription Sponsor/company: sanofi-aventis ClinicalTrials.gov
More informationModified-release dipyridamole combined with aspirin for secondary stroke prevention
For reprint orders, please contact: reprints@futuremedicine.com DRUG EVALUATION Modified-release dipyridamole combined with aspirin for secondary stroke prevention Hans-Christoph Diener University Essen,
More informationLOW DOSE ASPIRIN CARDIOVASCULAR DISEASE FOR PROPHYLAXIS OF FOR BACKGROUND USE ONLY NOT TO BE USED IN DETAILING
LOW DOSE ASPIRIN FOR PROPHYLAXIS OF CARDIOVASCULAR DISEASE FOR BACKGROUND USE ONLY NOT TO BE USED IN DETAILING Use of Low Dose Aspirin to Treat and Prevent Cardiovascular Disease In recent decades, aspirin
More informationNova Scotia Guidelines for Acute Coronary Syndromes (Updating the 2008 Antiplatelet Section of the Guidelines)
Cardiovascular Health Nova Scotia Guideline Update Nova Scotia Guidelines for Acute Coronary Syndromes (Updating the 2008 Antiplatelet Section of the Guidelines) Authors: Dr. M. Love, Dr. I. Bata, K. Harrigan
More informationCorporate Medical Policy
Corporate Medical Policy File Name: Origination: Last CAP Review: Next CAP Review: Last Review: measurement_of_thromboxane_metabolites_for_asa_resistence 01/01/2019 N/A 01/01/2020 01/01/2019 Description
More informationPlatelet resistance is best defined as a lack of the desired pharmacologic effect
2Chapter 1 Anti-Platelet Resistance Oral Antiplatelet Therapy Resistance: Definition, diagnosis, and clinical implications Saurabh Gupta, MD Peter J. Casterella, MD Executive Summary Platelet resistance
More informationTicagrelor compared with clopidogrel in patients with acute coronary syndromes the PLATO trial
compared with clopidogrel in patients with acute coronary syndromes the PLATO trial August 30, 2009 at 08.00 CET PLATO background In NSTE-ACS and STEMI, current guidelines recommend 12 months aspirin and
More informationAntiplatelet Therapy in Primary CVD Prevention and Stable Coronary Artery Disease. Καρακώστας Γεώργιος Διευθυντής Καρδιολογικής Κλινικής, Γ.Ν.
Antiplatelet Therapy in Primary CVD Prevention and Stable Coronary Artery Disease Καρακώστας Γεώργιος Διευθυντής Καρδιολογικής Κλινικής, Γ.Ν.Κιλκίς Primary CVD Prevention A co-ordinated set of actions,
More informationThe Clopidogrel in Unstable angina to prevent Recurrent ischemic Events (CURE) Trial
Benefits and Risks of the Combination of Clopidogrel and Aspirin in Patients Undergoing Surgical Revascularization for Non ST-Elevation Acute Coronary Syndrome The Clopidogrel in Unstable angina to prevent
More informationCollectively, the efficacy of the intravenous glycoprotein
Increased Mortality With Oral Platelet Glycoprotein IIb/IIIa Antagonists A Meta-Analysis of Phase III Multicenter Randomized Trials Derek P. Chew, MBBS; Deepak L. Bhatt, MD; Shelly Sapp, MS; Eric J. Topol,
More informationPercutaneous Coronary Interventions Without On-site Cardiac Surgery
Percutaneous Coronary Interventions Without On-site Cardiac Surgery Hassan Al Zammar, MD,FESC Consultant & Interventional Cardiologist Head of Cardiology Department European Gaza Hospital Palestine European
More informationEvaluation of Clopidogrel Resistance. in ischemic stroke patients.
ORIGINAL ARTICLE Evaluation of Clopidogrel Resistance in Ischemic Stroke Patients Takuya Fukuoka, Daisuke Furuya, Hidetaka Takeda, Tomohisa Dembo, Harumitu Nagoya, Yuji Kato, Ichiro Deguchi, Hajime Maruyama,
More informationAspirin Resistance Current Issues
REVIEW ARTICLE JIACM 2009; 10(3): 134-9 Aspirin Resistance Current Issues NS Neki* Abstract In the last few years, the concept of aspirin resistance has been largely emphasised in the medical literature,
More informationThe Role of Aspirin in Cardiovascular Prevention
Journal of the American College of Cardiology Vol. 51, No. 19, 2008 2008 by the American College of Cardiology Foundation ISSN 0735-1097/08/$34.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2007.11.080
More informationQUT Digital Repository:
QUT Digital Repository: http://eprints.qut.edu.au/ This is the author s version of this journal article. Published as: Doggrell, Sheila (2010) New drugs for the treatment of coronary artery syndromes.
More informationHeart disease is the leading cause of death
ACS AND ANTIPLATELET MANAGEMENT: UPDATED GUIDELINES AND CURRENT TRIALS Christopher P. Cannon, MD,* ABSTRACT Acute coronary syndrome (ACS) is an important cause of morbidity and mortality in the US population
More informationAntiplatelet Therapy After PCI: How Much and How Long?
Antiplatelet Therapy After PCI: How Much and How Long? Adnan Kastrati Deutsches Herzzentrum, Munich, GERMANY Antiplatelet Therapy after PCI: How much and how long? The simplest and extreme response: Give
More informationClinical Lessons from BMC2-PCI
Clinical Lessons from BMC2-PCI The Blue Cross Blue Shield of Michigan Cardiovascular Consortium Hitinder Gurm, M.D. University of Michigan Overview 32 papers since inception 10 papers published this year
More informationPlatelet glycoprotein IIb/IIIa inhibition in acute coronary syndromes
European Heart Journal (00) 3, 1441 1448 doi:10.1053/euhj.00.3160, available online at http://www.idealibrary.com on Platelet glycoprotein IIb/IIIa inhibition in acute coronary syndromes Gradient of benefit
More informationJournal of the American College of Cardiology Vol. 45, No. 9, by the American College of Cardiology Foundation ISSN /05/$30.
Journal of the American College of Cardiology Vol. 45, No. 9, 2005 2005 by the American College of Cardiology Foundation ISSN 0735-1097/05/$30.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2005.01.030
More informationΠΑΝΕΠΙΣΤΗΜΙΟ ΙΩΑΝΝΙΝΩΝ. Εξατοµικευµένη αντιαιµοπεταλιακή αγωγή. Ποιο είναι το µέλλον?
ΠΑΝΕΠΙΣΤΗΜΙΟ ΙΩΑΝΝΙΝΩΝ ΕΡΕΥΝΗΤΙΚΟ ΚΕΝΤΡΟ ΑΘΗΡΟΘΡΟΜΒΩΣΗΣ Εξατοµικευµένη αντιαιµοπεταλιακή αγωγή. Ποιο είναι το µέλλον? Αλέξανδρος Δ. Τσελέπης, MD, PhD Καθηγητής Βιοχηµείας - Κλινικής Χηµείας Disclosures
More informationJournal of the American College of Cardiology Vol. 35, No. 4, by the American College of Cardiology ISSN /00/$20.
Journal of the American College of Cardiology Vol. 35, No. 4, 2000 2000 by the American College of Cardiology ISSN 0735-1097/00/$20.00 Published by Elsevier Science Inc. PII S0735-1097(99)00643-9 Early
More informationVerifyNow Reference Guide
VerifyNow Reference Guide Interventional Procedure Patients with inadequate response to their antiplatelet medications may be at significantly greater risk of myocardial infarction, stent thrombosis and
More information2010, Metzler Helfried
Perioperative Strategies in Patients on Dual Antiplatelet Drug Therapy: Noncardiac Surgery H. Metzler Department of Anaesthesiology and Intensive Care Medicine Medical University of Graz, Austria What
More informationWhy and How Should We Switch Clopidogrel to Prasugrel?
Case Presentation Why and How Should We Switch Clopidogrel to Prasugrel? Shaul Atar Western Galilee Medical Center Nahariya, ISRAEL Case Description A 67 Y. Old Pt. admitted to IM with anginal CP. DM,
More informationS PECIAL A RTICLE. Combination Antiplatelet Therapy: Implications for Pharmacists
S PECIAL A RTICLE Combination Antiplatelet Therapy: Implications for Pharmacists Robert L. Talbert, Pharm.D., FCCP, Sarah A. Spinler, Pharm.D., FCCP, Jean M. Nappi, Pharm.D., FCCP, and Michael B. Bottorff,
More information7 th Munich Vascular Conference
7 th Munich Vascular Conference Secondary prevention of major cardiovascular events in patients with CHD or PAD - What can we learn from EUCLID and COMPASS, evaluating Clopidogrel, Ticagrelor and Univ.-Prof.
More informationKorea University Guro Hospital, Seoul, Korea * Chonnam National University Hospital, Gwangju, Korea
Left Main Disease versus Non Left Main Disease in Acute Myocardial Infarction Patients in Real world Clinical Practice : Lessons from Korea Acute Myocardial Infarction Registry (KAMIR) Seung-Woon Rha*,
More informationHow Long Patietns Will Be on Dual Antiplatelet Therapy?
How Long Patietns Will Be on Dual Antiplatelet Therapy? Ron Waksman,, MD, FACC Professor of Medicine (Cardiology) Georgetown University Associate Director, Division of Cardiology, Washington Hospital Center
More informationTiming of Surgery After Percutaneous Coronary Intervention
Timing of Surgery After Percutaneous Coronary Intervention Deepak Talreja, MD, FACC Bayview/EVMS/Sentara Outline/Highlights Timing of elective surgery What to do with medications Stopping anti-platelet
More informationJOINT MEETING OF CORONARY REVASCULARIZATION 2014 TIONG LEE LEN SENIOR RESEARCH PHARMACIST CLINICAL RESEARCH CENTER, SARAWAK GENERAL HOSPITAL
The Effect of Non Steady State and Steady State Clopidogrel Carboxylic Acid Plasma Concentration on Clopidogrel Responsiveness in Patients Planned For Percutaneous Coronary Intervention JOINT MEETING OF
More informationDr Julia Hopyan Stroke Neurologist Sunnybrook Health Sciences Centre
Dr Julia Hopyan Stroke Neurologist Sunnybrook Health Sciences Centre Objectives To learn what s new in stroke care 2010-11 1) Acute stroke management Carotid artery stenting versus surgery for symptomatic
More informationIMMATURE PLATELETS CLINICAL USE
HAEMATOLOGY FEBRUARY 217 WHITE PAPER IMMATURE PLATELETS CLINICAL USE Identifying poor antiplatelet drug response and its risks early on Platelets are important cells for repairing endothelial lesions,
More information9/29/2015. Primary Prevention of Heart Disease: Objectives. Objectives. What works? What doesn t?
Primary Prevention of Heart Disease: What works? What doesn t? Samia Mora, MD, MHS Associate Professor, Harvard Medical School Associate Physician, Brigham and Women s Hospital October 2, 2015 Financial
More informationNovel Risk Markers in ACS (Hyperglycemia, Anemia, GFR)
Novel Risk Markers in ACS (Hyperglycemia, Anemia, GFR) Shaul Atar, MD Department of Cardiology Faculty of Medicine of the Galilee Western Galilee Medical Center, Nahariya, Israel TIMI Risk Score Age 65
More informationDiabete ed ASA: cosa c è di nuovo?
Università Magna Græcia di Catanzaro Dipartimento di Medicina Sperimentale e Clinica Cattedra di Medicina Interna ed U.O. Malattie Cardiovascolari Scuola di Specializzazione in Geriatria Prof. Francesco
More informationIs There A LIfe for DES after discontinuation of Clopidogrel
EMBARGOED UNTIL 3:45pm CT, Sunday, 11/16/14 - FOR MEDIA BACKGROUND ONLY - Do Not Publish Chicago 2014 Is There A LIfe for DES after discontinuation of Clopidogrel Six-month versus 24-month dual antiplatelet
More informationBelinda Green, Cardiologist, SDHB, 2016
Acute Coronary syndromes All STEMI ALL Non STEMI Unstable angina Belinda Green, Cardiologist, SDHB, 2016 Thrombus in proximal LAD Underlying pathophysiology Be very afraid for your patient Wellens
More informationDECLARATION OF CONFLICT OF INTEREST. None declared
DECLARATION OF CONFLICT OF INTEREST None declared Coronary Artery Disease, Aspirin, and Perioperative Myocardial Infarction and Bleeding in Orthopedic Surgery Brandon Oberweis, MD*, Swetha Nukala, MBBS*,
More informationOUTPATIENT ANTITHROMBOTIC MANAGEMENT POST NON-ST ELEVATION ACUTE CORONARY SYNDROME. TARGET AUDIENCE: All Canadian health care professionals.
OUTPATIENT ANTITHROMBOTIC MANAGEMENT POST NON-ST ELEVATION ACUTE CORONARY SYNDROME TARGET AUDIENCE: All Canadian health care professionals. OBJECTIVE: To review the use of antiplatelet agents and oral
More informationWhat is the role of dual antiplatelet therapy with clopidogrel and aspirin?
INTERPRETING KEY TRIALS CME CREDIT MIHIR R. BAKHRU, MD Department of Internal Medicine, Cleveland Clinic DEEPAK L. BHATT, MD * Associate Director, Cardiovascular Coordinating Center, Section of Cardiac,
More informationControversies in PCI A young cardiologist s perspective
Controversies in PCI A young cardiologist s perspective Antiplatelet Tx, PLT function monitoring should be mandatory CONTRA M. Valgimigli, MD, PhD Ferrara, Italy Euro-PCR Session @ ESC August 30th 2010,
More informationClinical Seminar. Which Diabetic Patient is a Candidate for Percutaneous Coronary Intervention - European Perspective
Clinical Seminar Which Diabetic Patient is a Candidate for Percutaneous Coronary Intervention - European Perspective Stephan Windecker Department of Cardiology Swiss Cardiovascular Center and Clinical
More informationPrasugrel vs. Ticagrelor in ACS/PCI Which one to choose? V. Voudris MD FESC FACC 2 nd Cardiology Division Onassis Cardiac Surgery Center
Prasugrel vs. Ticagrelor in ACS/PCI Which one to choose? V. Voudris MD FESC FACC 2 nd Cardiology Division Onassis Cardiac Surgery Center Hospitalizations in the U.S. Due to ACS Acute Coronary Syndromes
More informationConflicts of Interest: None. Aspirin, primary prevention and USPSTF. Primary prevention of ASCVD is important
Aspirin, primary prevention and USPSTF Presented by: Craig Williams, PharmD., BCPS., FNLA; February 2017 Conflicts of Interest: None Primary prevention of ASCVD is important Myocardial Infarction Incidence
More informationMultiplate analyzer Cut-off-values ADPtest and ASPItest
Multiplate analyzer Cut-off-values ADPtest and ASPItest Cut-off values ADPtest The cut-off values were established in hirudin blood samples. Healthy individuals AUC (U) 1 Patient on ADP receptor antagonist
More information